Clinical efficacy of tetrandrine in artificial stone-associated silicosis: A retrospective cohort study
Frontiers in Medicine · 17.02.2023 · 10
DOI: 10.3389/fmed.2023.1107967 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Frontiers in Medicine, online erschienen am 17.02.2023. Verfasst von Wen-Hong Wu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pneumoconiosis, Shanghai Pulmonary Hospital, Tongji University, Shanghai, China. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Outbreaks of silicosis have occurred among workers in the artificial stone (AS) industry, and there is currently no effective antifibrosis treatment for silicosis.
Design
A retrospective cohort study.
Methods
We retrospectively analyzed the clinical data of 89 artificial stone-associated silicosis patients treated in Shanghai Pulmonary Hospital (China). Patients who agreed to be administered tetrandrine entered the observation group and those who disagreed entered the control group. Changes in chest HRCT, pulmonary function, and clinical symptoms of patients in two groups were compared pre- and post-treatment.
Results
After treatment for 3–12 months, 56.5%–65.4% of patients in the observation group showed improvements in HRCT imaging, while there was no improvement in the control group ( p < 0.05). Disease progression occurred in 0%–17.4% of patients in the observation group after 3–12 months of treatment compared with 44.4%–92.0% of patients in the control group ( p < 0.05). After 3 months of treatment, the forced vital capacity (FVC), forced expiratory volume in 1 s (FEV 1 ), and diffusing capacity of the lung for carbon monoxide (DLco) in the observation group increased by 136.7 ± 189.2 mL ( p < 0.05), 124.2 ± 169.9 mL ( p < 0.05), and 1.4 ± 2.3 mL/min/mmHg ( p > 0.05), respectively, while those in the control group decreased (145.8 ± 356.5; 107.5 ± 272.1; 1.9 ± 3.8). After 6 months of treatment, FVC, FEV 1 , and DLco in the observation group increased by 207.8 ± 372.2 mL ( p > 0.05), 107.8 ± 295.2 mL ( p > 0.05) and 0.7 ± 6.0 mL/min/mmHg ( p > 0.05), respectively, while those of the control group decreased (383.3 ± 536.7; 215.6 ± 228.9; 1.4 ± 1.7). The incidences of clinical symptoms such as cough, expectoration, dyspnea, chest tightness, and chest pain in the observation group were decreased-after treatment (all p < 0.05), while the incidences of these symptoms increased in the control group, although the change was not statistically significant (all p > 0.05).
Conclusion
Tetrandrine can control and delay the progression of AS-associated silicosis fibrosis, with improved chest HRCT imaging and pulmonary function.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pneumoconiosis, Shanghai Pulmonary Hospital, Tongji University, Shanghai, China.
- Shanghai Key Laboratory of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University, Shanghai, China.
- School of Public Heath, The Key Laboratory of Environmental Pollution Monitoring and Disease Control, Ministry of Education, Guizhou Medical University, Guiyang, China.
- The Fifth People's Hospital of Suzhou, Suzhou, China.
- Department of Pulmonary Function Test, Shanghai Pulmonary Hospital, Tongji University, Shanghai, China.
- Department of Health, Qingyang District Center for Disease Control and Prevention, Chengdu, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wu, W. H., Feng, Y. H., Min, C. Y., Zhou, S. W., Chen, Z. D., Huang, L. M., Yang, W. L., Yang, G. H., Li, J., Shi, J., Quan, H., & Mao, L. (2023). Clinical efficacy of tetrandrine in artificial stone-associated silicosis: A retrospective cohort study. Frontiers in Medicine, 10. https://doi.org/10.3389/fmed.2023.1107967
Vancouver
Wu WH, Feng YH, Min CY, Zhou SW, Chen ZD, Huang LM, et al. Clinical efficacy of tetrandrine in artificial stone-associated silicosis: A retrospective cohort study. Frontiers in Medicine. 2023;10. doi:10.3389/fmed.2023.1107967
BibTeX
@article{Wu2023,
author = {Wu, Wen-Hong and Feng, Yong-Hong and Min, Chun-Yan and Zhou, Shao-Wei and Chen, Zi-Dan and Huang, Li-Min and Yang, Wen-Lan and Yang, Guang-Hong and Li, Jun and Shi, Jin and Quan, Hua and Mao, Ling},
title = {Clinical efficacy of tetrandrine in artificial stone-associated silicosis: A retrospective cohort study},
journal = {Frontiers in Medicine},
year = {2023},
volume = {10},
doi = {10.3389/fmed.2023.1107967}
}
EUVIMED